Atopic Dermatitis (Eczema)
67
12
16
33
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
13 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.0%
4 terminated out of 67 trials
89.2%
+2.6% vs benchmark
19%
13 trials in Phase 3/4
39%
13 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 33 completed trials
Clinical Trials (67)
Clinical Trial to Evaluate the Efficacy and Safety of an Ozonated Oil in Atopic Dermatitis
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
The Effects of an L-histidine-Based Supplement, Eczema Topical, and Unscented Soap on Children With Eczema
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
Global Healthcare Study on Atopic Dermatitis
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Seal, Stopping Eczema and Allergy Study
Breast Milk: Influence of the Micro-transcriptome Profile on Atopy in Children Over Time
The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Tofacitinib for Immune Skin Conditions in Down Syndrome
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Moisturization and Skin Hydration Study